NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.91 -1.20 (-5.97 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$18.91
Today's Range$18.75 - $20.50
52-Week Range$12.04 - $25.00
Volume122,790 shs
Average Volume85,444 shs
Market Capitalization$369.95 million
P/E Ratio-10.62
Dividend YieldN/A
Beta3.22
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis. It also engages in the research and production of lab kits. The company has a strategic research collaboration with GE Healthcare Life Science to co-develop industrial control processes in chimeric antigen receptor T-cell and stem cell manufacturing; and Novartis to manufacture and supply the CAR-T cell therapy KymriahÂ. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in Cupertino, California.

Receive CBMG News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBMG
CUSIPN/A
Phone408-973-7884

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$340,000.00
Book Value$3.77 per share

Profitability

Net Income$-25,490,000.00
Net Margins-13,988.39%

Miscellaneous

Employees125
Market Cap$369.95 million
OptionableOptionable

Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

How will Cellular Biomedicine Group's stock buyback program work?

Cellular Biomedicine Group declared that its board has initiated a share repurchase program on Sunday, June 4th 2017, which permits the company to buyback $10,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback programs are often a sign that the company's leadership believes its stock is undervalued.

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group Inc (NASDAQ:CBMG) released its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.04. The biotechnology company earned $0.07 million during the quarter, compared to analysts' expectations of $0.05 million. Cellular Biomedicine Group had a negative net margin of 13,988.39% and a negative return on equity of 44.62%. View Cellular Biomedicine Group's Earnings History.

When is Cellular Biomedicine Group's next earnings date?

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Cellular Biomedicine Group.

What price target have analysts set for CBMG?

2 brokerages have issued 12-month price targets for Cellular Biomedicine Group's shares. Their forecasts range from $38.00 to $38.00. On average, they expect Cellular Biomedicine Group's stock price to reach $38.00 in the next year. This suggests a possible upside of 101.0% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

What is the consensus analysts' recommendation for Cellular Biomedicine Group?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

Has Cellular Biomedicine Group been receiving favorable news coverage?

News stories about CBMG stock have trended somewhat positive on Saturday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.

Who are some of Cellular Biomedicine Group's key competitors?

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the folowing people:
  • Mr. Bizuo Liu, CEO, CFO & Director (Age 54)
  • Dr. Yihong Yao, Chief Scientific Officer (Age 51)
  • Mr. Andrew K. Chan, Sr. VP of Corp. Bus. Devel., Sec. & Chief Legal Officer (Age 61)
  • Dr. Xia Meng Ph.D., BS, Gen. Mang. of Early Diagnosis & Intervention
  • Derrick C. Li, Head of Strategy & Investor Relations

Who are Cellular Biomedicine Group's major shareholders?

Cellular Biomedicine Group's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meeder Asset Management Inc. (0.02%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

Which institutional investors are buying Cellular Biomedicine Group stock?

CBMG stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

How do I buy shares of Cellular Biomedicine Group?

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of CBMG stock can currently be purchased for approximately $18.91.

How big of a company is Cellular Biomedicine Group?

Cellular Biomedicine Group has a market capitalization of $369.95 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-25,490,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. Cellular Biomedicine Group employs 125 workers across the globe.

What is Cellular Biomedicine Group's official website?

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com.

How can I contact Cellular Biomedicine Group?

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]


MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  257
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Featured Article: Correction

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel